Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SMC

- PMLiVE

GSK plans sirukumab filing in rheumatoid arthritis next year

Says phase III trials showed 'no unexpected safety findings'

Gilead Sciences

Gilead steps into breach left by AbbVie as Galapagos’ partner

Deal worth $2bn to help rheumatoid arthritis drug filgotinib make it through to the market

- PMLiVE

Lucid behavioural change programmes recognised at PMEA

Agency wins awards for initiatives for AbbVieand Genzyme

- PMLiVE

AbbVie takes Company of the Year at PMEA 2015

Firm rewarded for patient-centricity, whileAstellas is highly commended

- PMLiVE

Amgen’s biosimilar shows clinical equivalence with Humira

ABP 501 as effective as AbbVie's blockbuster in phase III rheumatoid arthritis trial

- PMLiVE

AbbVie looks to put bronchiolitis awareness back on the agenda

Relaunches More Than a Cold campaign

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

- PMLiVE

Lilly’s baricitinib beats Humira in trial for RA

Posts positive phase III data against the world's biggest-selling drug

- PMLiVE

AbbVie drops Galapagos JAK inhibitor to focus on ABT-494

Believes ABT-494 has potential to become best-in-class therapy

- PMLiVE

AbbVie’s Humira wins ninth US approval

FDA approves multi-blockbuster for inflammatory skin disease

National Institute for Health and Care Excellence NICE logo

NICE set to recommend seven biologics for severe rheumatoid arthritis

List includes Roche's RoActemra and biosimilars Inflectra and Remsima

- PMLiVE

India denies patent on Pfizer’s Xeljanz

Drug deemed not an invention because it is not more effective than original compound

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links